A detailed history of Morgan Stanley transactions in Rezolute, Inc. stock. As of the latest transaction made, Morgan Stanley holds 79,029 shares of RZLT stock, worth $347,727. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,029
Previous 400,246 80.25%
Holding current value
$347,727
Previous $1.72 Million 77.75%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.13 - $5.31 $1.33 Million - $1.71 Million
-321,217 Reduced 80.25%
79,029 $383,000
Q2 2024

Oct 17, 2024

BUY
$2.29 - $5.79 $911,820 - $2.31 Million
398,175 Added 19226.22%
400,246 $1.72 Million
Q2 2024

Aug 14, 2024

BUY
$2.29 - $5.79 $911,820 - $2.31 Million
398,175 Added 19226.22%
400,246 $1.72 Million
Q1 2024

Oct 17, 2024

SELL
$0.95 - $2.55 $378,266 - $1.02 Million
-398,175 Reduced 99.48%
2,071 $5,000
Q4 2023

Aug 16, 2024

SELL
$0.74 - $1.24 $294,649 - $493,737
-398,175 Reduced 99.48%
2,071 $2,000
Q4 2022

Feb 14, 2023

BUY
$1.38 - $2.84 $2,788 - $5,739
2,021 Added 4042.0%
2,071 $4,000
Q3 2022

Nov 14, 2022

BUY
$2.19 - $3.49 $63 - $101
29 Added 138.1%
50 $0
Q4 2021

Feb 14, 2022

SELL
$4.21 - $7.61 $2,109 - $3,812
-501 Reduced 95.98%
21 $0
Q3 2021

Nov 15, 2021

BUY
$7.45 - $13.66 $3,888 - $7,130
522 New
522 $4,000

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $171M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.